Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) announced the publication of its PCT patent application for a novel machine learning solution predicting blood-brain barrier (BBB) permeability. The technology has shown exceptional performance, processing up to 100,000 molecules per hour with industry-leading accuracy, with Lantern's AI algorithms holding five of the top eleven positions on the Therapeutic Data Commons Leaderboard.

The proprietary technology integrates advanced molecular representation techniques with synthetic data augmentation, processed by machine learning algorithms through Lantern's RADR® AI platform. The company's subsidiary, Starlight Therapeutics, plans to implement this technology for STAR-001 development. The PCT application allows Lantern to pursue worldwide patent protection for 20 years from filing, with expedited review initiated in the United States.

Positive

• Patent application received favorable PCT search report indicating no significant prior art
• Technology demonstrates industry-leading accuracy in BBB permeability prediction
• System processes up to 100,000 molecules per hour
• Algorithms hold 5 of top 11 positions on Therapeutic Data Commons Leaderboard
• Patent protection potential extends 20 years from filing date

Negative

• None.

Insights

AI & Drug Development Technology Analyst

Lantern Pharma's PCT patent application for their blood-brain barrier (BBB) permeability prediction model represents a significant strategic asset with multiple revenue potential streams. The technology's exceptional performance metrics - processing 100,000 molecules per hour with industry-leading accuracy - positions Lantern as a potential leader in CNS drug development technology.

The favorable PCT search report, indicating no significant prior art, substantially strengthens Lantern's intellectual property position. This creates a 20-year protection window in major markets worldwide, establishing a robust competitive moat. The technology's integration with their RADR® AI platform creates a comprehensive drug development ecosystem that could attract pharmaceutical partnerships and licensing opportunities.

Three key commercial implications stand out:

• The technology can significantly reduce early-stage drug development costs by quickly identifying viable candidates for CNS-targeted therapies
• Integration with subsidiary Starlight Therapeutics' STAR-001 development demonstrates immediate practical application
• The development of sophisticated sub-models incorporating protein binding and active transport mechanisms suggests ongoing innovation potential

The market opportunity is substantial, considering that CNS drug development has historically been challenged by the blood-brain barrier's complexity. By addressing this critical bottleneck, Lantern positions itself as a valuable partner for pharmaceutical companies developing treatments for brain cancers and neurological disorders.

The technology's scalability and accuracy metrics suggest potential for both internal drug development acceleration and external partnership opportunities. The planned expedited review in the United States could accelerate commercialization timelines, potentially leading to near-term revenue generation through licensing or collaboration agreements.

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting blood-brain barrier (BBB) permeability. The application received a favorable PCT search report indicating no significant prior art, substantially strengthening its path to approval.

The technology has demonstrated to-date exceptional performance in predicting BBB permeability across a wide range of chemical compounds, processing up to 100,000 molecules per hour with industry-leading accuracy. Notably, Lantern's AI algorithms for BBB permeability prediction currently hold five of the top eleven positions on the Therapeutic Data Commons Leaderboard¹. Lantern believes that this breakthrough capability can accelerate the drug development process by rapidly identifying compounds likely to cross the blood-brain barrier, a critical factor in developing treatments for central nervous system disorders and brain cancers. These identified compounds can then be accelerated and further developed by researchers in cancer drug development and other fields saving time and cost in early-stage molecular characterization.

"The publication of this PCT patent application represents a significant advancement in our AI-driven approach to drug development," stated Panna Sharma, Chief Executive Officer of Lantern Pharma. "This innovative technology not only enhances our internal development capabilities but also offers transformative potential for our partners and collaborators across the pharmaceutical industry. The system's exceptional speed and accuracy in predicting BBB permeability positions Lantern at the forefront of CNS-targeted therapeutic development. We look forward to deploying this high-performing BBB model in collaboration with pharmaceutical partners and techbio-driven companies who seek to accelerate their development timelines while working with a partner committed to excellence, especially in the area of high-performing, predictive models for drug development."

The proprietary technology integrates advanced molecular representation techniques with synthetic data augmentation from features engineered from the chemical structure and bioactivity data which are then processed by leading-edge machine learning algorithms. Through integration with Lantern's RADR® AI platform, the system enables rapid and comprehensive assessment of both drug candidates and other molecules of interest for BBB permeability.

Lantern's wholly-owned subsidiary, Starlight Therapeutics, intends to implement this technology to advance the development of STAR-001 and evaluate additional drug candidates. In addition, Lantern is actively expanding the system's capabilities through the development of sophisticated sub-models that account for complex biological factors affecting BBB permeability. These enhancements are expected to further refine predictions by incorporating advanced features such as protein binding, active transport mechanisms, and disease-state modifications of the blood-brain barrier. This continued evolution of the technology demonstrates Lantern's commitment to maintaining its leadership position in AI-driven drug development.

The PCT application enables Lantern to pursue patent protection in major markets worldwide, with potential coverage extending 20 years from the filing date. The company has initiated expedited review in the United States to accelerate market deployment.

This technological advancement reinforces Lantern's position as an innovator in AI-driven drug development and strengthens its ability to develop more effective, targeted CNS cancer therapies. The company expects this development to significantly impact both its internal drug development pipeline and future collaboration opportunities.

ABOUT LANTERN PHARMA

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR^®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.

Please find more information at:

• Website: www.lanternpharma.com
• LinkedIn: https://www.linkedin.com/company/lanternpharma/
• X: @lanternpharma

FORWARD LOOKING STATEMENTS:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: the potential advantages of our novel machine learning solution for predicting blood-brain barrier (BBB) permeability covered by PCT patent application (PCT/US2024/019851); the likelihood that the claims covered by PCT patent application (PCT/US2024/019851) will be subject to an issued patent in the U.S. or any foreign country; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; and our intention to leverage the proprietary technology covered by PCT patent application (PCT/US2024/019851) to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," “model,” "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that no U.S. or foreign patents are issued with respect to the novel machine learning solution for predicting blood-brain barrier (BBB) permeability covered by PCT patent application (PCT/US2024/019851); (ii) if we are able to secure issued patents, the risk that we do not realize the expected advantages of any such patents; (iii) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

¹Therapeutics Data Commons is a resource to access and evaluate AI methods, supporting the development of AI methods, with a strong bent towards establishing the foundation of which AI methods are most suitable for drug discovery applications and why. It can facilitate algorithmic and scientific advances and accelerate AI method development, validation and transition into biomedical and clinical implementation. The Commons curates benchmarks for key therapeutic tasks. Every benchmark has a carefully designed ML task, ML-ready dataset, a public leaderboard, and a set of performance metrics to support model evaluation, providing effective indicators of the performance of ML methods in real-world scenarios. Visit https://tdcommons.ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219931339/en/

Investor Relations

ir@lanternpharma.com

(972)277-1136

Source: Lantern Pharma Inc.

FAQ

What is the significance of LTRN's new blood-brain barrier permeability prediction technology?

The technology can process 100,000 molecules per hour with industry-leading accuracy, accelerating drug development by quickly identifying compounds likely to cross the blood-brain barrier, important for CNS and brain cancer treatments.

How many top positions does LTRN hold on the Therapeutic Data Commons Leaderboard?

Lantern Pharma's AI algorithms for BBB permeability prediction hold five of the top eleven positions on the Therapeutic Data Commons Leaderboard.

What is the patent protection duration for LTRN's new BBB permeability technology?

The PCT application enables Lantern to pursue patent protection worldwide for 20 years from the filing date.

How will Starlight Therapeutics use LTRN's new BBB permeability technology?

Starlight Therapeutics, Lantern's wholly-owned subsidiary, plans to implement this technology to advance the development of STAR-001 and evaluate additional drug candidates.